These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 25426701

  • 1. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V, Baabbad R, Hammerby E, Nikolajsen A, Shafie AA.
    J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
    [Abstract] [Full Text] [Related]

  • 2. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes.
    Shafie AA, Gupta V, Baabbad R, Hammerby E, Home P.
    Diabetes Res Clin Pract; 2014 Nov; 106(2):319-27. PubMed ID: 25305133
    [Abstract] [Full Text] [Related]

  • 3. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U, Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Saokaew S.
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ.
    Value Health; 2009 Jun; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [Abstract] [Full Text] [Related]

  • 5. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R.
    Clin Ther; 2005 Jun; 27 Suppl B():S75-88. PubMed ID: 16519039
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G.
    Clin Ther; 2005 Jun; 27 Suppl B():S57-74. PubMed ID: 16519038
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1 chieve study.
    Almansari A, Khader S, Kharawagh A, AbdelFattah W, Badawy T.
    Int J Clin Pract; 2014 Jul; 68(7):850-6. PubMed ID: 24548757
    [Abstract] [Full Text] [Related]

  • 8. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ.
    Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
    [Abstract] [Full Text] [Related]

  • 9. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.
    Valentine WJ, Pollock RF, Plun-Favreau J, White J.
    Curr Med Res Opin; 2010 Jun; 26(6):1399-412. PubMed ID: 20387997
    [Abstract] [Full Text] [Related]

  • 10. 15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.
    Liebl A, Mohan V, Yang W, Strojek K, Linjawi S.
    Drugs R D; 2018 Mar; 18(1):27-39. PubMed ID: 29468559
    [Abstract] [Full Text] [Related]

  • 11. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
    Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S.
    Curr Med Res Opin; 2005 Dec; 21(12):2063-71. PubMed ID: 16368057
    [Abstract] [Full Text] [Related]

  • 12. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.
    Farshchi A, Aghili R, Oskuee M, Rashed M, Noshad S, Kebriaeezadeh A, Kia M, Esteghamati A.
    BMC Endocr Disord; 2016 Jun 09; 16(1):35. PubMed ID: 27278922
    [Abstract] [Full Text] [Related]

  • 13. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008 Jun 09; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China.
    Palmer JL, Beaudet A, White J, Plun-Favreau J, Smith-Palmer J.
    Adv Ther; 2010 Nov 09; 27(11):814-27. PubMed ID: 21061114
    [Abstract] [Full Text] [Related]

  • 15. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
    Soewondo P, Lindarto D, Wibisono S, Renaldi O, Dalem-Pemayun TG.
    Diabetes Res Clin Pract; 2013 Apr 09; 100 Suppl 1():S41-6. PubMed ID: 23647718
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.
    Curr Med Res Opin; 2009 May 09; 25(5):1273-84. PubMed ID: 19366302
    [Abstract] [Full Text] [Related]

  • 17. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study.
    Balaji V, Balaji MS, Alexander C, Srinivasan A, Suganthi SR, Thiyagarajah A, Seshiah V.
    Gynecol Endocrinol; 2012 Jul 09; 28(7):529-32. PubMed ID: 22468861
    [Abstract] [Full Text] [Related]

  • 18. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
    Lim-Abrahan MA, Yu-Gan S, Jain AB, Sobrepena LM, Racho VA.
    Diabetes Res Clin Pract; 2013 Apr 09; 100 Suppl 1():S35-40. PubMed ID: 23647717
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting.
    Palmer JL, Knudsen MS, Aagren M, Thomsen TL.
    J Med Econ; 2010 Apr 09; 13(2):212-20. PubMed ID: 20350145
    [Abstract] [Full Text] [Related]

  • 20. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
    Dempsey M, Mocarski M, Langer J, Hunt B.
    J Med Econ; 2018 Nov 09; 21(11):1110-1118. PubMed ID: 30114954
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.